CardioDx In The News

Blood-Based Gene Expression Test Beats MPI for Ruling Out Obstructive CAD
December 14, 2011
Diagnostic and Interventional Cardiology The results of the COMPASS (Coronary Obstruction Detection by Molecular Personalized Gene Expression) trial were presented at the American Heart Association Scientific Sessions 2011 conference in Orlando, Fla.

CardioDx Passes Trial, Determining When Chest Pain Is No Big Deal
November 15, 2011
Xconomy Chest pain is one of the big reasons people go to the ER or to see their primary care doc. Often when people get there, it’s hard to tell who has serious heart disease or something less serious.

Blood test better for coronary arteries
November 15, 2011
UPI.com A blood test is more effective to rule out obstructive coronary artery disease than a test that uses a radioactive agent, U.S. researchers say.

Study: Corus CAD demonstrates superiority to MPI
November 15, 2011
Fierce Medical Devices CardioDx saw good news from Florida this week with the presentation of results from the COMPASS trial involving Corus CAD, a blood-based gene expression test for obstructive coronary artery disease.

Blood test catches clogged arteries
October 27, 2011
America Now The Centers for Disease Control says heart disease is the leading cause of death in the United States.

CardioDx fills CFO, chief medical officer posts
September 19, 2011
San Francisco Business Times A veteran Bay Area biotech chief financial officer and a former investment bank analyst have joined CardioDx Inc. in senior management jobs.

Healthline: Corus CAD Heart Test
July 5, 2011
WAFB, Baton Rouge, LA It's not unheard of. A person's sent home from the hospital with a clean bill of health, only to drop dead of a heart attack.

3 New Medical Tests that Can Save Your Life—But You Have to Ask
June 17, 2011
Forbes.com A few weeks ago a local politician in my area died of a massive heart attack at 49, while on a lighthearted ski weekend in Tahoe with his buddies.

CardioDx to Use $60M Funding Round to Make Clinical Utility Case for Corus CAD (pdf)
May 18, 2011
Pharmacogenomics Reporter CardioDx has raised $60 million in equity financing that it will invest in expanding reimbursement for its Corus CAD genetic test for coronary artery disease.

Predicting Heart Attacks!
February 7, 2011
Ivanhoe Today Every 35 seconds, an America dies of heart disease. If your family has a history of heart attacks or stroke, you are twice as likely to have one yourself.

Medscape Cardiology: A Genetic Test to End Angiography?
January 21, 2011
Medscape Today A Best Evidence Interview With Eric J. Topol, MD
A free Medscape account is required to view article.

Health Watch: Blood Test for Chest Pain
January 13, 2010
FOX News, Atlanta, GA Chest pain can be frightening.  But doctors now have a new way of diagnosing the heart blockages that may be causing the problem.

The New Wave of Medical Tests That Could Save Your Life
December 10, 2010
Caring.com We've all heard the scary stories. Someone in his 40s, seemingly in perfect health, suddenly drops dead during his morning run.

Blood Test for Heart Attack; The Top 10 Everything of 2010
December 9, 2010
TIME A heart attack starts with blockages in the blood vessels, so where better to look for predictors of heart trouble than in the blood?

The Winners, Category by Category
September 27, 2010
Wall Street Journal This year the Innovation Awards judges chose winners in 17 categories. Here's a look at the winning entries.

Completing the Picture (pdf)
May 24, 2010
BioCentury By teaming up to promote each other's tests for coronary artery disease, CardioDx Inc. and General Electric Co.'s GE Healthcare unit believe they can provice more complete answers to physicians and patients than is possible with either test alone.

CardioDx: Bringing Molecular Diagnostics into the Cardiovascular Arena (pdf)
March 25, 2010
In Vivo Buoyed by their success with Genomic Health, a trio of West Coast VCs have expanded their portfolios of molecular diagnostic companies, with many following similar themes. CardioDx has developed a test to distinguish between patients who should move on to cardiac imaging and those they are comfortable managing otherwise.

CardioDx Launches Gene Test for Obstructive Coronary Disease (pdf)
September 7, 2009
The Gray Sheet CardioDx is gradually rolling out its Corus CAD gene expression test, which quantifies the likelihood of obstructive coronary artery disease in patients with stable chest pain and no previous history of cardiac disease

New Gene Expression Test will make Diagnosing Coronary Artery Disease Simpler
September 1, 2009
HCPLive.com CardioDX, a cardiovascular genomic diagnostics company, has completed a multi-center study validating the effectiveness of Corus CAD...

CardioDx Completes Study of Genetic Test for Coronary Artery Disease
September 1, 2009
Diagnostic and Invasive Cardiology CardioDx said last week it successfully completed its multicenter validation study for Corus CAD, the first gene expression test to quantify the likelihood of obstructive coronary artery disease (CAD) in patients with stable chest pain.

CardioDx Completes Validation Study of Genomic Test for Coronary Artery Disease
August 26, 2009
Clinical Lab Products CardioDx, a cardiovascular genomic diagnostics company, announces that the company has successfully completed its multicenter validation study for Corus™ CAD, the first and only gene expression test to quantify the likelihood of obstructive coronary artery disease (CAD) in patients with stable chest pain.

CardioDx Completes Multicenter Validation Study For Corus CAD
August 25, 2009
Pharmaceutical Business Review Gene expression test to quantify the likelihood of obstructive CAD in patients with stable chest pain.

Executive Spotlight: David Levison, Founder, CEO and Director of CardioDx
August 24, 2009
California Healthcare Institute Blog CardioDx is a personalized medicine company that develops and commercializes genetic based cardiac diagnostic tests.